FIELD: medicine.
SUBSTANCE: claimed invention relates to field of biotechnology. Claimed method of treating tumour in mammal, including introduction of efficient quantity of fusion protein ALK1-Fc, where fusion protein ALK1-Fc contains extracellular domain (ECD) similar to activin receptor-like kinase I (ALK1 or ACVRL1), fused at C-end with Fc-region of immunoglobulin.
EFFECT: fusion protein ALK1-Fc in accordance with invention is capable of binding GDF5, GDF7 and BMP9, providing inhibition of development of blood vessels.
16 cl, 10 dwg, 8 ex
